Action HZNP HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Horizon Therapeutics Public Limited Company

Actions

HZNP

IE00BQPVQZ61

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
AQ
Rule 17(d) Announcement, Horizon Therapeutics plc
AQ
Rule 17(e) Announcement - Horizon Therapeutics plc
BU
Rule 17(d) Announcement – Horizon Therapeutics plc
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics plc Announces New UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder to be presented at ECTRIMS 2023
AQ
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics - New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA to Support Thyroid Eye Disease Patient Outcomes
AQ
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics plc Named to U.S. News & World Report's 2024 List of Best Companies to Work For in the Health Care Industry
AQ
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
BU
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
BU
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
BU
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
BU
FTC, States Agree On Path Forward For Amgen's Horizon Therapeutics Deal
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HZNP
  4. Actualités Horizon Therapeutics Public Limited Company
  5. Communiqués